Status | Study |
Active, not recruiting |
Study Name: Multicenter Observational Study of Myotonic Dystrophy Type 1 Condition: Myotonic Dystrophy Type 1 Date: 2014-12-02 |
Recruiting |
Study Name: Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1 Condition: Myotonia Congenita (Enrollment Complete) Paramyotonia Congenita Date: 2014-09-25 Interventions: Drug: Ranolazine Ranexa is FDA approved for chronic angina |
Active, not recruiting |
Study Name: Observational Prolonged Trial in Myotonic Dystrophy Type 1 Condition: Myotonic Dystrophy Type 1 Date: 2014-04-11 Interventions: Behavioral: Behavioural change intervention The intervention is cognitive behaviour therapy (CBT). The C |
Active, not recruiting |
Study Name: Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Condition: Myotonic Dystrophy Type 1 Date: 2013-12-04 |
Completed |
Study Name: Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy Condition: Myopathy Date: 2012-02-08 Interventions: Device: Nocturnal ventilation Home ventilation only the mode AVAPS will be used if the patient is random |
Completed |
Study Name: Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 Condition: Myotonic Dystrophy Date: 2011-07-20 Interventions: Drug: Mexiletine 150 mg/kg Mex |
Completed |
Study Name: Methylphenidate in Myotonic Dystrophy Type 1 Condition: Dystrophia Myotonica 1 Date: 2011-06-01 Interventions: Drug: Methylphenidate One Tabl |
Completed |
Study Name: Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Condition: Myotonic Dystrophy Date: 2010-11-15 Interventions: Other: Supine spirometry In addition to the current upright lung function evaluation we performed a supi |
Completed |
Study Name: DM1 Heart Registry - DM1 Respiratory Registry Condition: Myotonic Dystrophy Date: 2010-06-02 |
Active, not recruiting |
Study Name: Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 Condition: Myotonic Dystrophy Type 1 Date: 2007-12-18 Interventions: Drug: rhIGF-I/rhIGFBP-3 1.0 mg |